{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:08:10Z","timestamp":1781762890398,"version":"3.54.5"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaad.2021.12.028","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:33:15Z","timestamp":1639999995000},"page":"655-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review"],"prefix":"10.1016","volume":"87","author":[{"given":"David","family":"Croitoru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Nathanielsz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Seigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawaan","family":"Elsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Zipursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2021.12.028_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.028_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ddg.12585","article-title":"Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts","volume":"13","author":"Al Ghazal","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.028_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11908-015-0478-5","article-title":"Rituximab causing deep ulcerative suppurative vaginitis\/pyoderma gangrenosum","volume":"17","author":"Selva-Nayagam","year":"2015","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.028_bib4","doi-asserted-by":"crossref","first-page":"e13221","DOI":"10.1111\/dth.13221","article-title":"Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis","volume":"33","author":"Aggarwal","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.028_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221029947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221029947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:03:43Z","timestamp":1759273423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221029947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0190962221029947"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}